Portfolio Companies

Antev Ltd., a subsidiary of Medicus Pharma Ltd (NASDAQ:MDCX,) is a clinical stage biotech company, developing Teverelix, a next generation gonadotrophin-releasing hormone GnRH antagonist, a potentially first in market product for high-risk prostate cancer patients and patients with first acute urinary retention (AUR) episodes due to enlarged prostate.